Jefferies Financial Group Boosts Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $54.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective increased by investment analysts at Jefferies Financial Group from $45.00 to $54.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Jefferies Financial Group’s price target would suggest a potential upside of 79.64% from the stock’s previous close.

A number of other research firms have also weighed in on KNSA. Wedbush reissued an “outperform” rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “buy” rating in a research note on Sunday, July 6th. Finally, Wells Fargo & Company raised their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 9th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Buy” and an average price target of $41.17.

Kiniksa Pharmaceuticals International Stock Down 1.0%

KNSA opened at $30.06 on Tuesday. Kiniksa Pharmaceuticals International has a twelve month low of $17.82 and a twelve month high of $31.92. The company has a 50-day moving average price of $28.19 and a 200 day moving average price of $23.89. The company has a market cap of $2.19 billion, a PE ratio of 751.69 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. The firm had revenue of $156.80 million during the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.08%. As a group, sell-side analysts expect that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

Insider Activity

In other news, CFO Mark Ragosa sold 18,299 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $28.80, for a total transaction of $527,011.20. Following the completion of the sale, the chief financial officer owned 27,009 shares in the company, valued at $777,859.20. This trade represents a 40.39% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ross Moat sold 27,594 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total transaction of $800,777.88. Following the sale, the insider owned 9,415 shares of the company’s stock, valued at $273,223.30. This represents a 74.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 320,981 shares of company stock worth $9,189,467 over the last quarter. 53.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $301,000. GAMMA Investing LLC increased its holdings in Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after purchasing an additional 568 shares during the last quarter. Nuveen Asset Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 7.3% in the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock valued at $15,737,000 after purchasing an additional 54,361 shares during the last quarter. Wellington Management Group LLP increased its holdings in Kiniksa Pharmaceuticals International by 46.3% in the 4th quarter. Wellington Management Group LLP now owns 69,813 shares of the company’s stock valued at $1,381,000 after purchasing an additional 22,096 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Kiniksa Pharmaceuticals International by 28.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 56,691 shares of the company’s stock valued at $1,121,000 after purchasing an additional 12,462 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.